摘要
We read with interest the recent article by Li et al.(1)reported a randomized phase III trial that compared the efficacy of hepatic artery infusion(HAIC)with oxaliplatin,fluorouracil,and leucovorin with transarterial chemoembolization(TACE)for large hepatocellular carcinoma(HCC)(diameter≥7 cm).The authors found a lower incidence of serious adverse events in the FOLFOX-HAIC group;furthermore,the overall and progression-free survival was better in the FOLFOX-HAIC group than in the TACE group.Likewise,HAIC provided survival benefits in various subgroups.However,although the authors discussed some limitations,several fundamental flaws have yet to be fixed.
